i Aspergillus disease affects a broad patient population, from patients with asthma to immunocompromised patients. Azole resistance has been increasingly reported in both clinical and environmental Aspergillus strains. The prevalence and clinical impact of azole resistance in different patient populations are currently unclear. This 1-year prospective multicenter cohort study aimed to provide detailed epidemiological data on Aspergillus resistance among patients with Aspergillus disease in Belgium. Isolates were prospectively collected in 18 hospitals (April 2011 to April 2012) for susceptibility testing. Clinical and treatment data were collected with a questionnaire. The outcome was evaluated to 1 year after a patient's inclusion. A total of 220 Aspergillus isolates from 182 patients were included. The underlying conditions included invasive aspergillosis (n ‫؍‬ 122 patients), allergic bronchopulmonary aspergillosis (APBA) (n ‫؍‬ 39 patients), chronic pulmonary aspergillosis (n ‫؍‬ 10 patients), Aspergillus bronchitis (n ‫؍‬ 7 patients), and aspergilloma (n ‫؍‬ 5 patients). The overall azole resistance prevalence was 5.5% (95% confidence interval [CI] 2.8 to 10.2%) and was 7.0% (4/57; 95% CI, 2.3 to 17.2%) in patients with APBA, bronchitis, aspergilloma, or chronic aspergillosis and 4.6% in patients with invasive aspergillosis (5/108; 95% CI, 1.7 to 10.7%). The 6-week survival in invasive aspergillosis was 52.5%, while susceptibility testing revealed azole resistance in only 2/58 of the deceased patients. The clinical impact of Aspergillus fumigatus resistance was limited in our patient population with Aspergillus diseases.
A spergilli are saprophytic molds, which are ubiquitous in our living environment. Aspergillosis represents a spectrum of disease affecting millions of people worldwide, ranging from lifethreatening angioinvasive infections in immunocompromised patients to chronic infections and allergic syndromes. Aspergillus fumigatus is the primary human-pathogenic species. According to the current international guidelines, voriconazole is the antifungal drug of choice in invasive aspergillosis (IA), and itraconazole is the antifungal drug of choice mainly in the chronic and allergic disease entities (1) . However, azole resistance can affect patients via two routes (2) . First, resistance can develop gradually during the course of antifungal therapy (3) . Second, azole-naive patients, such as most IA patients, may have azole-resistant disease when they become infected with a strain which gained resistance properties externally (4) . In the latter, only a few predominant resistance mechanisms occur, namely, the CYP51A alterations TR 34 / L98H and TR 46 /Y121F/T289A (4, 5) . Such resistant strains are selected in the environment by the agricultural use of azole fungicides (2) . Since 2007, reports of A. fumigatus azole resistance have emerged from different countries and patient populations. The prevalence of "environmental resistance" ranges from 0 to 6.5%, with the highest percentage reported in the Netherlands (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . The ongoing spread of environmental resistance in Europe and outside of Europe is of clinical concern. Whether azole resistance is an independent risk factor for clinical failure remains uncertain. A threshold rate of resistance prevalence that would trigger a change in the empirical therapeutic regimen is yet to be determined (14) . In real-life registries, the first-line use of voriconazole has been consistently and independently associated with improved responses and decreased IA-attributable mortality compared with those for other mold-active agents (15) (16) (17) (18) . Detailed epidemiological findings are essential to the debate at hand. The public health risk associated with environmental triazole use has recently been assessed by the European Centre for Disease Prevention and Control but remains inconclusive since resistance development is poorly understood and its patient and economic impacts need further investigation (19) .
This 1-year prospective multicenter cohort study aimed to investigate the prevalence of azole resistance in Belgium, among patients with Aspergillus disease, and its clinical impact.
MATERIALS AND METHODS
Clinical surveillance. (i)Inclusion criteria. Aspergillus spp. cultured from clinical samples were prospectively collected in 18 Belgian hospitals caring for intensive care, hematology, and/or transplant patients from April 2011 to April 2012. Only isolates from patients with documented Aspergillus disease were included. The participating microbiologists evaluated the clinical relevance of positive cultures by review of the medical files and the patients' laboratory, radiology, and pathology data, in consultation with the treating physician. IA cases were classified as "proven" or "probable" disease following the revised European Organization for Research and Treatment of Cancer Mycoses Study Group (EORTC/MSG) definitions (20) . In addition, patients with a high clinical suspicion of IA, with no other apparent cause of disease and no response to broad-spectrum antibiotics, for whom mold-active antifungal therapy was initiated, were included despite not fulfilling the EORTC/MSG criteria (referred to as f Galactomannan positivity has been analyzed for blood at the cutoff for positivity (index of 0.5) and in BAL fluid at the cutoff for positivity (index of 0.8) and separately at a BAL fluid index of 3.0, as this latter cutoff corresponds to a specificity of 100% (28) . g One patient was lost to follow-up. The level of significance (P) was calculated with Fisher's exact test (for proportions), the t test for independent samples (age), or the MannWhitney test (GM medians).
"non-EORTC/MSG IA" in the remainder of the text). The principal investigators assessed whether the latter cases fulfilled the criteria for "putative" IA, as postulated by Blot et al. (21) . Of note, the criteria of Blot et al. are host and clinical criteria designed to judge Aspergillus cultured from bronchoalveolar (BAL) fluid or endotracheal aspirate specimens only. In this study, we also judged patients with sputum cultures as eligible for putative IA, if galactomannan (GM) (an Aspergillus antigen) positivity in blood (index of Ն0.5) or BAL fluid (index of Ն0.8) specimens supported the sputum culture as microbiological evidence.
Patients with non-EORTC/MSG IA and chronic obstructive pulmonary disease (COPD) were also assessed according to the criteria designed by Bulpa et al. (22) .
Allergic bronchopulmonary aspergillosis (ABPA) was defined following the minimal diagnostic criteria from the Cystic Fibrosis Foundation Consensus Conference (23) . Isolates from patients with acute ABPA, ABPA exacerbation, and ABPA remission were included. Isolates from patients with chronic necrotizing (CNPA), cavitary (CCPA), or fibrosing (CFPA) pulmonary aspergillosis, single sinus or lung aspergilloma, or Aspergillus bronchitis were identified based on clinical, radiological, and serological findings (total IgE, specific IgE, and specific IgG) (24, 25) . Table S1 in the supplemental material summarizes all diagnostic criteria. The susceptibility result of a maximum of one isolate of the same species/ patient/month was included, unless the susceptibility differed by interpretation for at least one azole.
(ii) Susceptibility testing. All Aspergillus isolates cultured in the participating centers were sent to the National Reference Center for Mycosis for analysis. Broth microdilution susceptibility testing was performed with pure substances of itraconazole (Janssen Pharmaceutica), voriconazole (Pfizer), and posaconazole (Merck), following the Clinical and Laboratory Standards Institute M38-A2 protocol. All Aspergillus colonies that grew were touched to prepare the inoculum (0.5 McFarland standard). The following interpretative criteria, based on epidemiological cutoff values (ECV), were applied for A. fumigatus: an itraconazole or voriconazole MIC of Յ1 mg/liter was considered susceptible, a MIC of 2 mg/liter intermediate, and a MIC of Ͼ2 mg/liter resistant; a posaconazole MIC of Յ0.25 mg/liter was considered susceptible, a MIC of 0.5 mg/liter intermediate, and a MIC of Ͼ0.5 mg/liter resistant (26) . Susceptibilities of isolates not belonging to the A. fumigatus complex were judged by conformance with their respective ECV (26) .
(iii) Genotyping. All Aspergillus isolates with non-wild-type susceptibility (an intermediate or resistant MIC to Ն1 tested azole) were identified with beta-tubulin sequencing (27) . Non-wild-type A. fumigatus sensu stricto isolates were also submitted to CYP51A sequencing, as published previously (10), but with an adaptation to primer AF766F (5=-TTCGGATCGGACGTGGTGT3-=) due to observed interference of the CYP51A-mutation Y121F with the original primer.
Statistical analysis. Clinical signs and symptoms, treatment regimens, underlying disease, and azole preexposure data were collected from the participating centers using a questionnaire. The outcome data were collected by review of the medical files up to 1 year after the patient's inclusion. This study was approved by the ethical committee at the University Hospitals Leuven, with reference S53024 (Belgian national reference B322201110423).
All statistical analyses were performed with GraphPad Software, Inc. The modified Wald method was used to calculate 95% confidence intervals (CI) for a proportion. The level of significance (P) was calculated with Fisher's exact test (proportions), the t test for independent samples (age), or the Mann-Whitney test (GM medians). Two-tailed P values of Ͻ0.05 were regarded as significant.
RESULTS
Clinical surveillance. In a 1-year period, 220 Aspergillus isolates were included. These isolates were harvested from 182 unique patients: 122 with IA (134 isolates), 39 with ABPA (54 isolates), 10 with chronic pulmonary aspergillosis (15 isolates), 7 with Aspergillus bronchitis (12 isolates), and 5 with a single aspergilloma (5 isolates). One ABPA patient developed probable IA later during the surveillance period. The species distribution of the causative isolates in the different disease entities is given in Table 1 . As Tables 2 and 3 . Proven IA and probable IA were diagnosed in 31 and 45 patients, respectively. Isolates from another 46 patients (mainly with underlying structural lung diseases), while not fulfilling the EORTC/MSG definitions (non-EORTC/MSG IA), were included. A total of 33/46 fulfilled the extended criteria for putative IA (n ϭ 25 patients) and/or the Bulpa et al. criteria in COPD patients (n ϭ 15 patients). The characteristics of the remaining unclassifiable (n ϭ 13/46) patients are summarized in Table S2 in the supplemental material. We observed significantly lower 6-week, 12-week, and 1-year survival rates in the non-EORTC/MSG IA patient category (P Ͻ 0.05) ( Table 2) . Susceptibility of the causative isolates in aspergillosis. The azole resistance rate and prevalence for the different Aspergillus diseases are given in Table 4 . The observed resistance rate was 5.7% (11/192 isolates; 95% CI, 3.1 to 10.1%) among the A. fumigatus complex isolates included. The resistance prevalence was 5.5% (9/164 unique patients with A. fumigatus isolation; 95% CI, 2.8 to 10.2%). CYP51A typing revealed the TR 34 /L98H-mechanism in 6 isolates (1 proven IA, 1 probable IA, 2 non-EORTC/ MSG IA [1 putative, 1 unclassifiable], 1 ABPA, and 1 Aspergillus bronchitis) and TR 46 /Y121F/T289A in 1 isolate (Aspergillus bronchitis). No CYP51A mutations were found in the remaining 4 resistant isolates from 2 patients. The patients with azole-resistant A. fumigatus disease are summarized in Table 5 . Another 22 A. fumigatus isolates had intermediate MICs to one (n ϭ 14) or two (n ϭ 8) triazoles. CYP51A alterations (F46Y/M172V/E427K in all but one) were discovered in 7/8 (88%) of the latter isolates, while CYP51A mutations were discovered in only 3/14 isolates (21%) with a single intermediate MIC (P Ͻ 0.01) (see Table S3 in the supplemental material). All A. fumigatus complex isolates with non-wild-type susceptibility were confirmed to be A. fumigatus sensu stricto through molecular identification.
Of the 25 patients with triazole exposure in the 6 months prior to Aspergillus culture, 9 patients (36%) were infected with a nonfumigatus species of Aspergillus (n ϭ 5) and/or with A. fumigatus with non-wild-type susceptibility (n ϭ 6). In 157 azole-naive patients, significantly fewer patients (n ϭ 25; 16%) were infected with a non-fumigatus species of Aspergillus (n ϭ 19) or A. fumigatus with non-wild-type susceptibility (n ϭ 6) (P ϭ 0.03). In Aspergillus spp. other than A. fumigatus, itraconazole resistance was observed in 9/10 A. niger complex isolates. The voriconazole and posaconazole MICs mainly equaled the ECV in these black aspergilli. Beta-tubulin sequencing revealed A. tubingensis, a species with known intrinsic itraconazole resistance, as the species involved. The itraconazole, voriconazole, and posaconazole MIC distributions of all isolates, according to azole preexposure, are shown in Fig. 1 .
DISCUSSION
Our national study was the first to evaluate the presence and clinical impact of azole resistance in clinically relevant Aspergillus spp. within the full spectrum of Aspergillus diseases. We report an overall resistance rate of 5.7% (95% CI, 3.1 to 10.1%) among A. fumigatus isolates and a resistance prevalence of 5.5% (95% CI, 2.8 to 10.2%) among unique patients with A. fumigatus culture positivity. Previous studies reported resistance rates from 0.6 to 11.2% in unselected clinical isolates (4) (5) (6) (7) (8) (9) (10) (29) (30) (31) . Even after correction for duplicate patients, the prevalence still varied from 1.1 to 8.0%. This range can be partly explained first by the incorporation of clinically irrelevant isolates and second by the patient case mix. These influencing factors make it difficult to evaluate the true variability in resistance prevalence across countries. The debate on the definition of a resistance prevalence threshold to leave voriconazole monotherapy as the initial therapeutic regimen in IA is mainly driven by the azole resistance percentages reported in our neighboring country, the Netherlands (prevalence of 63/921, 6.8%) (5) . The Dutch figure is obtained by subculturing unselected clinical isolates on azole-containing agars, with microdilution susceptibility testing (the gold standard) performed to confirm positive isolates. This approach allows screening of high numbers of clinical isolates and has proved useful for determining trends in the prevalence of azole resistance (5) . The resistance prevalence in our study is not significantly different (P ϭ 0.6) from the Dutch one, despite the large methodological differences. This establishes the clinical validity of resistance percentages obtained with a screening approach. However, the clinical impact of azole resistance in IA was limited in our study. The 6-week survival of patients with IA was 52.5% (64/122), but there was evidence for azole resistance in only 2/58 of the deceased patients. One deceased patient with azole-resistant IA was treated with liposomal amphotericin B from day 1 of his infection, so there is no evidence for a causal relation between azole resistance and therapy failure in this patient. Three voriconazole-treated patients with azole-resistant IA survived, of whom two patients had immune recovery. Only itraconazole resistance was observed in the remaining surviving patient (no CYP51A-mediated mechanism) ( Table 5 ). Among the 58 deceased patients, 35 patients received a voriconazole-containing regimen within the first week of antifungal therapy (60.3%) compared to 55/64 surviving patients (85.9%) (P ϭ 0.002).
We included not only IA patients who fulfilled the revised EORTC/MSG criteria for proven and probable IA, but also patients in whom IA was highly suspected despite nonconformity with these criteria (46/122 IA patients, 37.7%). The size of this second group underscores the need to better identify IA in atypical patient populations, given the high 6-week mortality rate in these patients. Additionally, all 6 patients with autopsy-proven IA would have been classified premortem as non-EORTC/MSG IA (5 putative IA and 1 unclassifiable).
When interpreting the resistance percentage reported here, one should consider that in clinical practice a sizeable number of patients have culture-negative aspergillosis. The diagnosis of IA is often based on GM positivity as "microbiological evidence" without culture positivity, especially in high-risk hematological patients. This has two consequences. First, the group of hematological patients with probable IA is probably underrepresented in our study (since a positive culture was an entry criterion). Second, a positive selection bias toward resistance in IA patients is plausible, as sampling procedures (such as BAL fluid) are more likely to be undertaken for patients in whom antifungal therapy fails.
Our study revealed that IA caused by A. tubingensis (8/122 IA patients, 6.6%) is as prevalent as IA caused by azole-resistant A. fumigatus (5/122, 4.1%) in Belgium. Furthermore, patients with azole preexposure are more frequently affected by non-A. fumigatus spp. than azole-naive patients. Research interest in the last decade has mainly focused on A. fumigatus, with a paucity of publications on non-A. fumigatus infections. More data are sought, as it is unclear if infections caused by non-A. fumigatus spp. lead to higher rates of azole therapy failure.
In patients with chronic and allergic Aspergillus disease caused by A. fumigatus, we report a resistance prevalence of 7.0% (4/57; 95% CI, 2.3 to 17.2%). A resistance prevalence as high as 17.8% (28/157) was reported from a specific referral center for patients with chronic and allergic aspergillosis (3) . A higher proportion of azole-preexposed patients is present in this subpopulation. However, in our study, the resistant isolates from this group also bear the environmentally evolved resistance mechanisms TR 34 /L98H and TR 46 /Y121F/T289A in 3 of 4 cases.
In conclusion, the resistance prevalence of A. fumigatus was 5.5% in a Belgian multicenter 1-year prospective cohort of patients with Aspergillus diseases. Our observations indicate that epidemiological follow-up is required, but at the same time the clinical implications should be seen in their true proportion in comparison to other factors that have an impact on the therapeutic efficacy and outcome in aspergillosis. E.V. received a personal research grant from the Research Foundation Flandres (Fonds Wetenschappelijk Onderzoek Vlaanderen). We received itraconazole pure substance as a kind gift from Janssen Pharmaceutica, voriconazole pure substance as a kind gift from Pfizer, and posaconazole pure substance as a kind gift from Merck.
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